Next-generation sequencing (NGS) has rapidly gained popularity as a diagnostic testing approach due to its unparalleled ability to comprehensively analyze genetic information with high throughput and precision. However, decentralized and small labs face significant hurdles when it comes to adopting NGS testing. From high upfront costs associated with acquiring the necessary equipment, to the complexity of bioinformatics tools and compliance management that require specialized expertise in data analysis and data security, adopting NGS poses challenges for labs with limited staff and infrastructure.

To empower small and decentralized labs to easily adopt NGS testing, QIAGEN has launched a new secondary analysis solution for oncology and inherited disease applications that enables high-throughput secondary analysis for use with any clinical NGS data. In this webinar, learn about QCI Secondary Analysis, an agnostic, cloud-based software-as-a-service (SaaS) solution that seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications.

In this webinar, attendees will learn how QCI Secondary Analysis:

. Streamlines analysis from a range of assay types, enabling labs to process more sequencing data without extensive time and resource investment.
. Ensures the highest degree of isolation and data protection, including compliance with ISO 27001, General Data Protect Regulation (GDPR), and the Health Insurance Portability and Accountability Act (HIPPA) requirements.
. Directly connects to QCI Interpret for an integrated and automated FASTQ-to-report workflow with limited hands-on time.